Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period

doi:10.19803/j.1672-8629.20220617

Abstract

Abstract: With the changes in Chinese pregnant populations in recent years, the proportion of medication during pregnancy is relatively high, and the risk of exposure to drugs during pregnancy has also been increased. Therefore, risk assessment of drug exposure during pregnancy is critical to drug safety during pregnancy. This article reviews the current drug exposure during perinatal pregnancy, drugs and teratogenic risk, and ways to engage in risk assessment and pharmaceutical care before summarizing the problems and challenges so as to standardize the development of pharmaceutical care and provide reference for improving the risk assessment system in China.

Key words: pregnant and maternal women, perinatal, medication safety, drug exposure, pregnancy, risk assessment, pharmaceutical care

CLC Number:

R969.3

WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.

References

[1] QIAO J, WANG Y, LI X et al. A Lancet commission on 70 years of women’s reproductive, maternal, newborn, child, and adolescent health in China[J].Lancet, 2021, 397(10293): 2497-2536.
[2] SUTAN R, AMINUDDIN NA, MAHDY ZA.Prevalence, maternal characteristics, and birth outcomes of preeclampsia: A cross-sectional study in a single tertiary healthcare center in greater Kuala Lumpur Malaysia[J].Front Public Health, 2022, 10: 973271
[3] LAOPAIBOON M.Advanced maternal age and pregnancy outcomes: a multicountry assessment[J].BJOG,20 14, 121(Suppl 1):49-56.
[4] GAI D, FENG X.New model of pharmaceutical care in drug safety of pregnant women[J].Practical Pharmacy and Clinical Remedies, 2019, 22(11): 1121-1124.
[5] ZHANG J, UNG C, GUAN X, et al.Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015[J]. BMC Pregnancy and Childbirth, 2019, 19(1): 459.
[6] HAAS DM, MARSH DJ, DANG DT, et al.Prescription and other medication use in pregnancy[J]. Obstet Gynecol, 2018, 131(5): 789-798.
[7] PATEL S, KUMAR M, BEAVER CJ, et al.Polypharmacy and cardiovascular diseases: consideration for older adults and women[J]. Curr Atheroscler Rep, 2022, 24(10): 813-820.
[8] KANTOR ED, REHM CD, HAAS JS, et al.Trends in prescription drug use among adults in the United States from 1999-2012[J]. JAMA, 2015, 314(17): 1818-1831.
[9] ZHANG C, ZHANG LL, WANG XD, et al.A comparative study of risk classification systems for drug use during pregnancy[J]. Chinese Pharmaceutical Journal, 2016, 51(103): 234-238.
[10] HOUBEN E, WINKEL BT, STEEGERS EAP, et al.Dutch trends in the use of potentially harmful medication during pregnancy[J].Br J Clin Pharmacol, 2020, 86(12):2377-2392.
[11] DAW JR.Prescription drug use during pregnancy in developed countries: a systematic review[J].Pharmacoepidemiol Drug Saf, 2011, 20(9): 895-902.
[12] GIVEN J, CASSON K, DOLK H, et al.Sociodemographic variation in prescriptions dispensed in early pregnancy in Northern Ireland 2010-2016[J].PLoS One, 2022,17(8): e0267710
[13] AYELE Y, MEKURIA AN, TOLA A, et al.Prescription drugs use during pregnancy in Ethiopia: a systematic review and meta-analysis[J]. SAGE Open Med, 2020, 8: 2050312120935471.
[14] ADANE F, SEYOUM G, ALAMNEH YM.Non-prescribed drug use and predictors among pregnant women in Ethiopia: systematic review and meta-analysis[J]. J Matern Fetal Neonatal Med, 2022, 35(22): 4273-4284.
[15] VARGESSON N.Thalidomide-induced teratogenesis: history and mechanisms[J]. Birth Defects Res C Embryo Today, 2015, 105(2): 140-156.
[16] TANGZR, XU XL, DENG SL, et al.Oestrogenic endocrine disruptors in the placenta and the fetus[J]. Int J Mol Sci, 2020, 21(4): 1519.
[17] CUMMINGS ED, KONG EL, EDENS MA.Gray Baby Syndrome[M/OL]. Treasure Island (FL): StatPearls Publishing, 2022. (2022-08-29)[2022-11-07].https://www.ncbi.nlm.nih.gov/books/NBK448133.
[18] CUNNINGHAM FG, LEVENO KJ, DASHE JS, et al.Williams Obstetrics[M]. 26^rd ed. New York, NY: McGraw-Hill, 2022.
[19] LI, Y, KIMFORD JM.Epilepsy and pregnancy[J]. Continuum (Minneapolis, Minn.), 2022, 28(1): 34-54.
[20] SESHACHALA BB, JOSE M, LATHIKAKUMARI AM, et al.Valproate usage in pregnancy: An audit from the Kerala Registry of Epilepsy and Pregnancy[J]. Epilepsia, 2021, 62(5):1141-1147.
[21] KAPLAN YC, DEMIR O.Use of phenytoin, phenobarbital carbamazepine, levetiracetam lamotrigine and valproate in pregnancy and breastfeeding: risk of major malformations, dose-dependency, monotherapy vs polytherapy, pharmacokinetics and clinical implications[J]. Curr Neuropharmacol, 2021, 19(11):1805-1824.
[22] FASS. Classification of medical products for use during pregnancy and lactation. The Swedish system[M]. Stockholm: LINFO, Drug Information Ltd., 1993.
[23] BLATTNER CM, DANESH M, SAFAEE M, et al.Understanding the new FDA pregnancy and lactation labeling rules[J]. Int J Women’s Dermatol, 2016, 2(1):5-7.
[24] BATAGOL R.Australian Drug Evaluation Committee: Medicines in pregnancy-an Australian categorisation of risk of drug use in pregnancy[M]. 3rd ed. Canberra, Australia: Australian Government Publishing Service, 1996.
[25] ZHANG C, ZHANG LL, ZENG LN, et al.A comparative study of different references to the fetal risk of drugs in pregnancy[J]. Chinese Journal of Evidenced-based Medicine, 2020, 20(7): 776-781.
[26] Wolters Kluwer Health.UpToDate[EB/OL]. [2022-09-12].https://www.uptodate.cn/.
[27] IBM Watson Health.Micromedex[EB/OL]. [2022-09-22].https://www.micromedexsolutions.com.
[28] BRIGGS GG, TOWERS CV, FORINASH AB.Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk[M]. 12th ed. R: Lippincott Williams& Wilkins(LWW), 2021.
[29] FDA: Pregnancy and Lactation Labeling Final Rule[EB/OL].(2019-07-12)[2022-07-08].https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.
[30] DU BR, CHEN Z, FENG XW.Analyzing briggs risk categorization for drugs during pregnancy and lactation[J]. Chinese Pharmaceutical Journal, 2021, 56(20):1637-1641.
[31] National Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China[M]. Beijing: China Medicineal Science Press,2020.
[32] YOU Y, HUANG FH, HAN L.Advances in reproduction toxicity study on traditional Chinese materia medica recorded in Chinese Pharmacopoeia as prohibited or used with caution during pregnancy[J]. Chin J Pharmacol Toxicol, 2018, 32(5):364-370.
[33] XIE XF.Study on the current situation and safety evaluation of Chinese patent medicines and Chinese herbal medicine used in pregnancy[D]. Chengdu: University of Electronic Science and Technoligy of China, 2021.
[34] WANG YG, JIN R, KONG XW, et al.Safety grade of application of traditional Chinese medicines during pregnancy[J]. China Journal of Chinese Materia Medica, 2016,41(1):150-153.
[35] YOU Y, HUANG FH, HAN L.Advances in reproduction toxicity study on traditional Chinese materia medica recorded in Chinese Pharmacopoeia as prohibited or used with caution during pregnancy[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2020, 36(2):97-100.
[36] WU CL, ZHOU JL.A preliminary study on the risk grading standard of traditional Chinese medicine during pregnancy[J]. CJTCM, 2014, 26(5):518.
[37] CHEN C.The status of Medication use and follow-up study of pregnancy outcomes in pregnant women consulted on drugs[D].Chengdu:University of Electronic Science and Technoligy of China, 2019.
[38] JING BW, GAI D, LI YF, et al.Effect of pregnant school courses taught by pharmacists on medication literacy of pregnant women[J].Clinical Medication Journal, 2022, 20(1):72-75.
[39] XIAO Y, LI YJ.Investigation of the current situation of medication safety awareness and the situation of drugs used of pregnant women[J]. Chin J Fam Plan, 2022, 30(4):734-737.
[40] GAI D, ZHAO W, LI YF, et al.Knowledge, attitudes and practices related to medication during pregnancy: a cross-sectional study among pregnant women in Beijing Obstetrics and Gynecology Hospital[J]. Clinical Medication Journal, 2019, 17(11): 75-78.
[41] TAO J, LI XH, TAN X, et al.Technical specification for consultation on the risk of drug teratogenicity during pregnancy[J].Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(4):393-401.
[42] Wolters Kluwer.Lexicomp: Evidence-Based Drug Referential Content[EB/OL]. [2022-09-15].https://www.wolterskluwer.com/en/solutions/lexicomp.
[43] Sichuan MEDICOM softwarere Search and Development Co.,Ltd. MCDEX[EB/OL]. [2022-09-15]. http://www.medicom.com.cn/Home/MCDEX.
[44] SCHAEFER C, PETERS P, MILLER RK.Pregnancy and lactation: treatment options and risk assessment[M]. Pittsburgh: Academic Press, 2015.